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Abstract
Objective—To determine whether the
introduction of genetic analysis for phenyl-
alanine hydroxylase (PAH) deficiency into
regional screening programmes can be
supported by the benefit-cost ratio.
Method—Tests for the genetic PAH locus
were carried out in 151 patients with
hyperphenylalaninaemia originally from
all of the Italian regions. PAH mutations
were identified by extraction of genomic
DNA from leucocytes (whole blood in
EDTA), PAH exon amplification was de-
termined by polymerase chain reaction,
restriction enzyme analysis was carried
out for some recognised mutations, and
DNA sequence analysis for the other
mutations.
Results—It was found that the eight most
common mutations in the population
accounted for 49% of the mutant alleles,
which is well below the required standard
for eVective population screening (90%).
Conclusions—Genetic screening for PAH
deficiency in Italy does not increase the
sensitivity of the methodology and the
benefit-cost ratio, and thus provides no
advantage, particularly as the correlation
between genotype and the metabolic
phenotype needed to optimise dietary
intervention is still being studied.
(J Med Screen 1999;6:193–194)
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Hyperphenylalaninaemia is caused by defi-
ciency of the phenylalanine hydroxylase (PAH;
EC 1.14.16.1) enzyme activity.1
The PAH gene, located on chromosome 12,
consists of 13 exons.2 According to the PAH
mutation analysis consortium, more than 300
diVerent mutations have been reported to
date.3 Each mutation may influence the
enzyme activity in a diVerent way, so that
various combinations of mutations result in a
spectrum of metabolic phenotypes, ranging
from severe, moderate, and mild phenyl-
ketonuria requiring strict dietary management,
to mild hyperphenylalaninaemia, in which the
dietary restriction of phenylalanine is not nec-
essary.
At present, newborn screening of hyper-
phenylalaninaemia is carried out by an immu-
noenzymatic assay on Guthrie card (normal
values of blood phenylalanine <180 µmol/l).
This simple, cheap test (costing around £2)
does not distinguish between patients with
phenylketonuria and mild hyperphenylalanin-
aemia.
When hyperphenylalaninaemia gene carriers
are screened, which is usually required by
parents and relatives of a patient with hyper-
phenylalaninaemia, the current biochemical
methods based on the phenylalanine loading
test (costing around £30) may misclassify
heterozygosity and normality in 10–20% of
cases.4
Genetic analysis—that is, identification of all
the PAH mutations characterised so far, would
provide a sensitivity of at least 98% (because
some mutations are located in unscreened
region of the PAH gene, such as introns or pro-
moter regions) and a specificity of 100% for
the test.5 The cost of such analysis has been
estimated as around £420 for both an aVected
patient and an identified carrier.
Advantages of the genetic test would be,
firstly, a 98% sensitivity in detection of PAH
carriers compared with a sensitivity of 80–90%
for the biochemical test and, secondly, early
discrimination between patients with phenyl-
ketonuria and mild hyperphenylalaninaemia.
The latter might lead to a definition of the
individual biochemical pattern before treat-
ment once the relation between genotype and
metabolic phenotype is shown.
This study aimed at identifying the most
common mutations in the Italian regions and
evaluating whether the introduction of genetic
analysis for PAH deficiency into regional
screening programmes could be supported by
the benefit-cost ratio.
Patients and methods
We tested for the genetic PAH locus in 151
patients with hyperphenylalaninaemia (con-
taining 15 sib pairs), corresponding to 272
unrelated alleles. The median age of the
patients, who came from all the Italian regions,
was 9.2 years (range 0.1–20.4); male/female
ratio 1.25.
Isolation of genomic DNA and amplification
of the 13 exons was carried out by standard
protocols.6 Denaturing gradient gel electro-
phoresis analysis of the polymerase chain reac-
tion (PCR)-amplified exons and flanking
intronic sequences of the PAH gene was
carried out as described by Guldberg et al.7
Samples with a pattern of bands diVering from
those of normal controls were further proc-
essed by sequence analysis. DNA sequencing
was carried out directly on PCR-amplified
products with the non-guanine-cytidine-
clamped primers of each exon, using the
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Applied Biosystem Model 310 DNA Sequenc-
ing System and the Rhodamine Terminator
Ready Reaction (Perkin Elmer, Italy).
Restriction enzyme analysis was used to
identify some recognised mutations (DdeI for
IVS10nt546, HinfI for R261Q, MluNI for
L48S, MspI for R158Q and P281L, HhaI for
A300S).8
The costs estimated throughout this paper
include both material and labour.
Results
Mutations were characterised in 227 of 272
(83%) unrelated alleles. Mutations for two
alleles were found in 102 patients, 11 sib pairs
(182 unrelated alleles) and a mutation for one
allele only was identified in 49 patients, four sib
pairs (45 unrelated alleles). Among the 49 dif-
ferent PAH mutations, we also identified three
new mutations at the PAH locus—two mis-
sense (L367V and Y417D) and one non-sense
(E380X).9 The prevalence of each identified
mutation was evaluated within the panel of the
272 unrelated alleles (table 1).
The eight most common mutations in our
population (R261Q, IVS10nt546, L48S,
P281L, Y414C, R158Q, R408W, A300S)
accounted for 49% of the mutant alleles—a
value that is well below the required standard
for eVective population screening (90%).
Fifty seven patients, including five sib pairs,
had two alleles mutant for one of the above
eight mutations. When the five sibling pairs
were excluded the sensitivity was 53% (only 52
aVected out of a total of 97 subjects), with a
cost of around £180 for each patient.
Conclusions
Our results confirm the high heterogeneity of
PAH gene mutations in Italy in comparison
with other countries. For example, in Denmark
four mutations account for 70% of the total,
and in Poland and Ireland a single mutation
accounts for around 40–50% of PAH mutant
alleles.10–12
Accordingly, genetic screening for PAH defi-
ciency in Italy does not increase the sensitivity
of the methodology and the benefit-cost ratio,
and thus cannot be proposed for use in that
country. Indeed, even if the sensitivity were
higher, the cost would still be prohibitive as the
correlation between genotype and metabolic
phenotype (and from this the possibility of
optimising dietary intervention) is still unclear.
In conclusion, genetic analysis in hyper-
phenylalaninaemia might provide additional
information on the metabolic phenotype in
those patients already identified as hyper-
phenylalaninaemic once a correlation between
genotype and metabolic phenotype has been
shown.13 However, further investigation of this
correlation is required.
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Table 1 Mutations of the phenylalanine hydroxylase gene
and their prevalence in a sample of Italian patients
No Mutation Exon
No of
alleles %
1 R261Q 7 26 9.5
2 IVS10nt546 10 25 9.2
3 L48S 2 18 6.6
5 Y414C 12 17 6.2
6 R158Q 5 16 5.9
4 P281L 7 15 5.5
7 R408W 12 8 2.9
8 A300S 8 8 2.9
9 R252W 7 4 1.8
10 E390G 11 4 1.5
11 Y204X 6 3 1.1
12 G352fsdelG 10 2 0.7
13 A395P 11 2 0.7
14 del F39 2 2 0.7
15 A395G 11 2 0.7
16 R68S 3 2 0.7
17 V230I 6 2 0.7
18 R297H 8 2 0.7
19 T287N 7 2 0.7
20 A259V 7 1 0.4
21 R408Q 12 1 0.4
22 V388M 11 1 0.4
23 R252Q 7 1 0.4
24 del l94 3 1 0.4
25 A309V 11 1 0.4
26 L15/S16fsdelCT 1 1 0.4
27 F55fs 2 1 0.4
28 I65T 3 1 0.4
29 E178G 6 1 0.4
30 C334S 10 1 0.4
31 D415N 12 1 0.4
32 V386C 11 1 0.4
33 T380M 11 1 0.4
34 IVS8nt1 g→a 9 1 0.4
35 E6nt96 A→g 6 1 0.4
36 R261X 7 1 0.4
37 D84Y 3 1 0.4
38 T92I 3 1 0.4
39 E360X 11 1 0.4
40 L367V 11 1 0.4
41 Y417D 12 1 0.4
42 IVS12nt1g→a 12 1 0.4
43 P366H 11 1 0.4
44 R176X 6 1 0.4
45 V245E 7 1 0.4
46 G257S 7 1 0.4
47 G247V 7 1 0.4
48 G257D 7 1 0.4
49 G257C 7 1 0.4
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